Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for High-risk neuroblastoma, drawn from the whole corpus: 14 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
About half of children relapse and relapsed disease is rarely cured.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
MYCN has no direct inhibitor; eflornithine and lorlatinib act around it.
Cisplatin hearing loss, infertility and second cancers in survivors of the most intensive regimen in paediatric oncology.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 22 changes by month →When this page itself was last checked or edited.
Maintenance to reduce relapse risk in high-risk neuroblastoma after ≥PR to prior therapy including anti-GD2
No patient had unacceptable toxicity and none was a feasibility failure over the first five induction cycles with dinutuximab and GM-CSF added.
ORR 63%, CR 33%; 3-year OS 60%.
EFS HR 0.
A milestone in how this cancer is treated.